Tourmaline Bio, Inc. (TRML)
Oct 28, 2025 - TRML was delisted (reason: acquired by NVS)
47.98
0.00 (0.00%)
Inactive · Last trade price on Oct 27, 2025
Tourmaline Bio Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 31.42 | 30.51 | 140.73 | 8.26 | 18.61 | 17.59 |
Short-Term Investments | 207.81 | 227.8 | 62.23 | - | 225.36 | 131.9 |
Cash & Short-Term Investments | 239.23 | 258.3 | 202.95 | 8.26 | 243.97 | 149.49 |
Cash Growth | -17.37% | 27.27% | 2357.63% | -96.61% | 63.20% | - |
Other Current Assets | 10.09 | 10.77 | 6.15 | 0.27 | 2.54 | 1.26 |
Total Current Assets | 249.1 | 268.84 | 208.87 | 8.31 | 246.51 | 150.75 |
Net Property, Plant & Equipment | 0.17 | 0.27 | 0.45 | 0.57 | 4.8 | 2.01 |
Long-Term Investments | 17.18 | 36.63 | - | - | - | - |
Other Long-Term Assets | 2.61 | 3.03 | 0.75 | - | 0.1 | 0.01 |
Total Assets | 269.3 | 309 | 210.3 | 9.1 | 251.42 | 152.78 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 3.17 | 3.58 | 1.07 | 0.4 | 2.56 | 0.77 |
Accrued Expenses | 6.78 | 5.1 | 3.71 | 0.8 | 5.43 | 2.64 |
Current Portion of Leases | 0.15 | 0.23 | 0.22 | 0.16 | - | - |
Total Current Liabilities | 10.1 | 8.91 | 5 | 1.36 | 7.99 | 3.4 |
Long-Term Leases | - | 0.02 | 0.19 | 0.34 | - | - |
Other Long-Term Liabilities | 0.01 | 0.02 | 0.06 | - | 0.63 | 1.37 |
Total Long-Term Liabilities | 0.01 | 0.04 | 0.25 | 0.34 | 0.63 | 1.37 |
Total Liabilities | 10.1 | 8.95 | 5.25 | 1.71 | 8.61 | 4.77 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Preferred Stock | - | - | - | 27.13 | - | 186.15 |
Common Stock | 0 | 0 | 0 | - | 0 | 0 |
Additional Paid-in Capital | 440.39 | 435.01 | 267.02 | 0.2 | 333.73 | 4.88 |
Accumulated Other Comprehensive Income | 0.12 | 0.3 | 0.07 | - | -0.08 | -0.01 |
Retained Earnings | -181.32 | -135.26 | -62.05 | -19.93 | -90.85 | -43.01 |
Shareholders' Equity | 259.19 | 300.05 | 205.04 | -19.73 | 242.81 | -38.15 |
Total Liabilities & Equity | 269.3 | 309 | 210.3 | 9.1 | 251.42 | 152.78 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 0.15 | 0.24 | 0.42 | 0.5 | 0 | 0 |
Net Cash (Debt) | 239.09 | 258.06 | 202.54 | 7.75 | 243.97 | 149.49 |
Net Cash Growth | -17.33% | 27.41% | 2512.02% | -96.82% | 63.20% | - |
Net Cash Per Share | 9.28 | 10.18 | 42.67 | 8.84 | 83.76 | 223.62 |
Book Value | 259.19 | 300.05 | 205.04 | -19.73 | 242.81 | -38.15 |
Book Value Per Share | 10.06 | 11.84 | 43.19 | -22.50 | 83.36 | -57.06 |
Tangible Book Value | 259.19 | 300.05 | 205.04 | -19.73 | 242.81 | -38.15 |
Tangible Book Value Per Share | 10.06 | 11.84 | 43.19 | -22.50 | 83.36 | -57.06 |